However, despite this promising preclinical evidence that synaptic alterations in SHANK3 deficiency may represent therapeutic targets, to date, there is a dearth of data, particularly in humans, on the abnormal neural systems underlying PMS. This evidence concerns the gene SHANK3 and premenstrual tension.